State Street SPDR S&P Biotech ETF XBI

SPDR S&P Biotech ETF (el Fondo) busca igualar de cerca los rendimientos y características del Índice de la Industria Selecta de Biotecnología S&P. El Índice de la Industria Selecta de Biotecnología S&P representa la porción de la subindustria de biotecnología del Índice de Mercados Totales S&P. El S&P TMI sigue todas las acciones comunes de Estados Unidos listadas en la Bolsa de Nueva York, la Bolsa de Valores de América, la Asociación Nacional de Corredores de Bolsa Cotización Automatizada (NASDAQ) Mercado Nacional y los intercambios NASDAQ Small Cap. El Índice de Biotecnología es un índice de peso igual modificado. SSgA Funds Management, Inc. es el asesor de inversiones del Fondo.

Con 6 acciones de XBI (USD 937,20) habrías recibido USD 3,30 en dividendos en los últimos 12 meses.

XBI hizo una división de acciones (split) de 3:1 el 11 de septiembre de 2015: cada acción se convirtió en 3. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 16 sept

  Should You Invest in the VanEck Biotech ETF (BBH)?

  The VanEck Biotech ETF (BBH) offers low-cost exposure to the biotech sector with a 0.35% expense ratio and $462.7 million in assets. The fund tracks the MVIS US Listed Biotech 25 Index and holds 26 companies with top holdings including Amgen, Gilead Sciences, and Vertex Pharmaceuticals. BBH has returned 21.89% year-to-date and 39.46% over the past year, but carries higher risk with a beta of 0.70 and 19.89% standard deviation. The fund received a Zacks ETF Rank of 2 (Buy).

  

• GlobeNewswire Inc. 3 sept

  PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company

  PVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.

  

• Zacks Investment Research 1 sept

  Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

  The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed fund offering broad exposure to the biotech sector with $2.91 billion in assets. The ETF has delivered strong performance with 29.36% gains year-to-date and 55.34% over the past year, though it carries higher risk with a beta of 0.66 and 20.71% standard deviation. With a 0.55% expense ratio and a Zacks ETF Rank of 2 (Buy), FBT is positioned as a solid option for biotech exposure, though larger competitors like IBB and XBI offer lower expense ratios.

  

• The Motley Fool 22 ago

  Breakfast News: A Conversation With Ionis CEO

  Ionis Pharmaceuticals CEO Brett Monia discusses the company's progress in 2026, highlighting FDA approval for Tryngolza and upcoming results for Pelacarsen in heart disease treatment. The company targets cash flow break-even in 2028 and projects $7 billion in peak revenue from late-stage programs. With 13 neurology drugs in clinical trials, Ionis aims to establish itself as a leader in antisense technology beyond first-mover competitors.

  

• The Motley Fool 8 ago

  iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

  The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) and State Street SPDR S&P Biotech ETF (XBI). XBI delivered superior 1-year returns of 80.2% with small-cap biotech focus but carries higher volatility (54% max drawdown). IXJ offers more stability with lower volatility, higher dividend yield (1.4%), and international diversification across large-cap pharmaceutical and healthcare companies. The analysis recommends XBI for long-term investors prioritizing performance despite greater risk.